Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma.

Biologics · 2017 · PMC5498675 · PMID 28721009

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

failed to reach statistical significancep =0.06so close (0.05 < p ≤ 0.1)

Although the study failed to show improvement in any clinical outcome measure despite significant reductions in the blood eosinophil count at both doses of active drug, a 50% reduction in severe exacerbations was observed during the follow-up period that failed to reach statistical significance ( p =0.06) as the study was not powered for this outcome.

also in 6,035 other papers

approached significancep =0.06so close (0.05 < p ≤ 0.1)

Despite this, it is notable that the study reported a trend toward reduction in severe exacerbation frequency that approached significance ( p =0.06), supporting an effect of treatment on this clinical outcome for the subgroup of subjects that were likely responders.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.